Crossref
26-A-16420-ACC APIXABAN VERSUS RIVAROXABAN IN ATRIAL FIBRILLATION PATIENTS RECEIVING CONCOMITANT DILTIAZEM
JACC · 2026-04 · 87 (13) · A130
DOI: 10.1016/j.jacc.2026.02.327 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC, 2026-04. Verfasst von Isadora Guarino und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Guarino, I., & Nazarian, S. (2026). 26-A-16420-ACC APIXABAN VERSUS RIVAROXABAN IN ATRIAL FIBRILLATION PATIENTS RECEIVING CONCOMITANT DILTIAZEM. JACC, 87(13), A130. https://doi.org/10.1016/j.jacc.2026.02.327
Vancouver
Guarino I, Nazarian S. 26-A-16420-ACC APIXABAN VERSUS RIVAROXABAN IN ATRIAL FIBRILLATION PATIENTS RECEIVING CONCOMITANT DILTIAZEM. JACC. 2026;87(13):A130. doi:10.1016/j.jacc.2026.02.327
BibTeX
@article{Guarino2026,
author = {Guarino, Isadora and Nazarian, Saman},
title = {26-A-16420-ACC APIXABAN VERSUS RIVAROXABAN IN ATRIAL FIBRILLATION PATIENTS RECEIVING CONCOMITANT DILTIAZEM},
journal = {JACC},
year = {2026},
volume = {87},
number = {13},
pages = {A130},
doi = {10.1016/j.jacc.2026.02.327}
}
EUVIMED